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Abstract
The measurement of cardiac troponins, either cardiac troponin I or T, has become the culprit of clinical decision making in patients with suspected 
acute coronary syndrome (ACS), especially in those with non-ST elevation myocardial infarction (NSTEMI). The leading analytical mainstays of car-
diac troponin immunoassays include the limit of blank (LoB), limit of detection (LoD), functional sensitivity, the 99th percentile of a healthy reference 
population, along with the percentage of “ostensibly healthy” subjects displaying measurable values < 99th percentile. The latest generation of 
cardiac troponin immunoassays, conventionally defined as “high-sensitive” (HS), is characterized by a LoD over 100-fold lower compared to the first 
commercialized techniques and a percentage of measurable values consistently > 50% in the general healthy population. The very recent commer-
cialization of methods with further improved analytical sensitivity (i.e., “ultra-sensitive” assays), which allow to measure cardiac troponin values in 
the vast majority of healthy subjects, is now challenging the diagnostic paradigm based on early rule-out of subjects with cardiac troponin values 
comprised between the 99th percentile and LoD. New diagnostic strategies, entailing assay-specific cut-offs, must hence be developed and validated 
in large multicenter studies. The aim of this article is to provide an update on commercially available HS and “ultra”-sensitive techniques for mea-
suring cardiac troponins, along with possible implications of increasingly enhanced analytical sensitivity on diagnostic algorithms for evaluating 
patients with suspected ACS.
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Review
Introduction
Despite many efforts made through the adoption 
of widespread preventive strategies, both morbid-
ity and mortality for acute coronary syndrome 
(ACS) remain extremely high. Thus, myocardial is-
chemia has become one of the leading health care 
challenges worldwide (1). Unlike many other hu-
man diseases, the diagnostic approach for patients 
with suspected ACS has undergone sizable and 
revolutionary changes since the release of the first 
diagnostic criteria by the World Health Organiza-
tion in the early 1970s (2). Irrespective of the pres-
ence of typical signs and symptoms of myocardial 
ischemia and suggestive electrocardiographic 
(ECG) abnormalities, the measurement of cardiac 
troponins (cTns), either cardiac troponin I (cTnI) or 
cardiac troponin T (cTnT), has become the culprit 
of making a specific clinical decision, particularly 
for diagnosing non-ST elevation myocardial infarc-
tion (NSTEMI) (3,4). Very recent evidence, combin-
ing organization and economic endpoints with di-
agnostic efficiency, also confirms that the meas-
urement of additional biomarkers, such as the cre-
atine kinase isoenzyme MB (CK-MB), impose a con-
siderable financial burden for the health care sys-
tem, without providing incremental value to pa-
tient care (5).
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Clinical use of high-sensitivity 
immunoassays
The universally agreed analytical mainstays of cTn 
testing are summarized in Tables 1 and 2, and sub-
stantially include limit of detection (LoD), limit of 
blank (LoB), functional sensitivity (also known as 
“Limit of Quantitation”; LoQ) and the 99th percen-
tile of a healthy reference population (6-8). 
The development and commercialization of cTn 
immunoassays started nearly 40 years ago, and 
progressed with the release of methods character-
ized by gradually enhanced analytical perfor-
mance, which are now gradually and irreversibly 
replacing the former generation of “contempo-
rary-sensitive” techniques (8). For example, the 
first-generation cTn immunoassays was character-
ized by LoD of approximately 500 ng/L and 0% of 
measurable values (i.e., concentration > LoD) in 
healthy subjects, while the latest generation of im-
munoassays is characterized by a LoD over 100-
fold lower compared to the original techniques 
and a percentage of measurable values typically > 
50% (9). A substantial revolution has followed the 
Assay imprecision (%) at a value corresponding to the 99th percentile
< 10 Guideline acceptable
10 - 20 Clinically useable
> 20 Not acceptable
Percentage (%) of measurable values < 99th percentile in healthy subjects
< 50 Contemporary-sensitive (CS) - Level 1
50 - 75 First-generation high-sensitive (HS) - Level 2
75 - 95 Second-generation high-sensitive (HS) - Level 3
> 95 Third-generation high-sensitive (HS) - Level 4
~ 99 - 100 Latest-generation high-sensitive (HS) - Level 5
Ratio between 99th percentile and LoD
< 1 Clinically useable, high-sensitive (HS)
≥ 10 Extremely high-sensitive (HS)
≥ 20 Ultra-sensitive (US)
LoD - limit of detection. 99th percentile - 99th percentile of a reference healthy population. Modified from (8).
Analytical quality specification Description
LoB Lowest signal generated in a fluid (i.e., typically the buffer or diluent of the assay) with zero cTn concentration.
LoD Value generated in a biological sample with the lowest measurable cTn concentration.
LoQ Minimal concentration of cTn that can be measured with ≤ 10% imprecision.
99th percentile Value of cTn corresponding to the 99
th percentile of a reference population of 
ostensibly healthy subjects.
Percentage of measurable values in healthy 
subjects
Percentage of cTn values < 99th percentile that can be obtained in a reference 
population of ostensibly healthy subjects.
cTn - cardiac troponin. LoB - limit of blank. LoD - limit of detection. LoQ - limit of quantitation (i.e. functional sensitivity).
Table 1. Analytical quality specifications of cardiac troponin immunoassays 
Table 2. Cardiac troponin immunoassay designations
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introduction of these so-called “high-sensitivity” 
(HS) immunoassays, driven by the recent evidence 
that patients with values of both cTnI and cTnT 
comprised between the LoD and the 99th percen-
tile (i.e., > LoD and < 99th percentile) or between 
the functional sensitivity of the immunoassay and 
the 99th percentile (i.e., > LoQ and < 99th percen-
tile) have a higher risk of unfavorable clinical out-
comes (both total and cardiovascular) compared 
to those with lower values (i.e., displaying cTn val-
ues < LoD or < LoQ) (10-15). Notably, such an en-
hanced risk of adverse events apparently lasts for a 
longer period after evaluation in the emergency 
rooms, since patients with values comprised be-
tween the 99th percentile and LoD (or the func-
tional sensitivity) also have an increased rate of 30-
day major adverse cardiovascular events (MACE). 
According to this paradigm, new diagnostic algo-
rithms no longer use the 99th percentile as the ref-
erence diagnostic threshold, but implement lower 
cTn cut-offs (i.e., conventionally identified with LoD 
or with the functional sensitivity) and entail short-
er-time serial testing (i.e., between 1 and 2 hours 
after baseline assessment, rather than 3 and 6 
hours afterwards) (16-21). The efficiency of this 
strategy for rapid rule-out of ACS and for identifi-
cation of patients with enhanced risk of 30-day 
MACE has already been proven in a consistent 
number of studies, and it is therefore predictable 
that this strategy may soon become the standard 
of care (10-15,22). Notably, the considerably im-
proved analytical performance of the new genera-
tion of cTn HS immunoassays may also allow intro-
ducing an additional “functional” classification of 
the methods, based on the ratio between the 99th 
percentile and LoD (Table 2). In clinical and labora-
tory practice, the larger the 99th percentile/LoD ra-
tio, the higher the probability to identify subjects 
with “measurable” values will be.
At the time of publication of this article, four fully-
automated HS immunoassays are commercially 
available and their analytical performance is sum-
marized in Table 3 (three for measuring cTnI and 
one for measuring cTnT, respectively) (23-27). Al-
though these techniques display different analyti-
cal performance and designation according to the 
conventional criteria of imprecision and analytical 
sensitivity, they are all characterized by a > 1 ratio 
between the 99th percentile and LoD (Table 3), 
thus making them clinically useable even when 
adopting the new diagnostic algorithms encom-
passing rule-out and short-time serial testing 
based on diagnostic thresholds corresponding to 
either the LoD or the functional sensitivity (7,8). 
Whether classifying the assays as clinically useable 
HS, extremely HS or “ultra-sensitive” (US) will de-
termine additional clinical advantages for early 
rule-in or rule-out of ACS, or for predicting the risk 
of 30-day MACE, remains to be demonstrated, 
since no comparison studies have been published 
so far. Nevertheless, improving further the analyti-
cal sensitivity of these methods (i.e., lowering both 
the LoD and functional sensitivity), may also chal-
lenge the new diagnostic paradigm of early rule-
out of subjects with cTn values comprised be-
tween the 99th percentile and the LoD. Interesting-
ly, the proportion of population with values <  99th 
percentile and > LoD has increased from 32% with 
Roche HS-cTnT to 97% with Beckman Coulter HS-
cTnI (Figure 1), thus generating new practical di-
lemmas: is it plausible that all the 97% ostensibly 
healthy subjects showing Beckman Coulter HS-cT-
Manufacturer Troponin Platform LoB (ng/L)
LoD 
(ng/L)
CV10% 
(ng/L)
99th percentile 
(ng/L)
Ratio 99th 
percentile/
LoD
Measurable 
values > 
LoD (%)
Beckman Coulter cTnI Access 0.1 0.3 1.3 16 53 97
Siemens cTnI ADVIA Centaur 0.5 2.2 2.7 48 22 80 - 95
Abbott cTnI ARCHITECT 0.7 - 1.3 1.1 - 1.9 5.6 19 10 - 17 57 - 75
Roche cTnT ELECSYS 3.0 5.0 12 14 3 32 - 42
cTnI - cardiac troponin I. cTnT - cardiac troponin T. LoB - limit of blank. LoD - limit of detection. CV10% - value with ≤ 10% analytical 
imprecision.
Table 3. Analytical performance of the four fully-automated high-sensitive cardiac troponin immunoassays commercially available
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nI values between the 99th percentile and the LoD 
should be considered at increased risk of ACS or 
30-day MACE compared to the remaining 3% of 
the population displaying unmeasurable values? 
And, even more challenging, how should these 
subjects be managed? Quite understandably, the 
new rule-out strategies based on LoD or function-
al sensitivity values as diagnostic cut-offs have 
been clinically validated using the former HS 
Roche HS-cTnT and Abbott HS-cTnI immunoassays, 
which display a 99th percentile/LoD ratio of 3 and 
10-17, respectively (23,24). Evidence has been pro-
vided showing that the standardization of cTn im-
munoassays is still an unmet target, even after har-
monization with common calibrators, so that diag-
nostic protocols validated using one cTn immuno-
assay may be inefficient when another technique 
is used (28). Notably, the two most recent Siemens 
and Beckman Coulter HS-cTnI immunoassays are 
characterized by a 99th percentile/LoD ratio > 20, 
and are hence more analytically sensitive. This 
would require developing specific algorithms for 
these methods.
Diagnostic algorithms with 
“ultra-sensitive” techniques
Given that a significant proportion of subjects 
with cTn values < 99th percentile are at enhanced 
risk of adverse cardiovascular events, the use of 
LoD or functional sensitivity as diagnostic thresh-
olds for early rule-out will be no longer feasible 
due to the obvious increased rate of false positive 
results using the so-called “US” techniques (Figure 
1). The decrease of the positive predictive value 
will likely be magnified as long as the analytical 
performance of the current immunoassays is im-
proved further, or when newer and even more an-
alytically sensitive techniques are commercialized. 
For example, a recent study aimed to investigate 
the analytical performance of the new Sgx cTnI As-
say (Singulex Inc., Alameda, USA) reported that the 
LoB, LoD and functional sensitivity of this assay are 
0.02, 0.08 and 0.53 ng/L, whilst measurable cTnI 
concentrations could be observed in as many as 
99.5% of healthy subjects (29). Paradoxically, these 
considerations pave the way to turn back the clock 
to nearly 40 years ago, when the strategy used for 
identifying the most efficient diagnostic thresh-
olds of cTns was based on receiver operating char-
acteristics (ROC) curve analysis (Figure 2). Indeed, 
the new cTn cut-offs for “US” technique will need 
to combine the best diagnostic performance at 
patient presentation with the risk of 30-day MACE, 
yielding a cTn value in the lower end of concentra-
tions comprised between the 99th percentile and 
the LoD. Although the timing of serial sampling af-
ter patient presentation should also be defined 
with large (and possibly multicenter) clinical stud-
ies, it is predictable that 0h/1h or 0h/2h time 
points may be efficient, reliable and safe using 
“US” techniques, since the reference delta cTn vari-
ation selected for optimal ruling-out or ruling-in 
ACS will now be characterized by excellent perfor-
mance in terms of analytical imprecision (i.e., much 
lower than 10%). Therefore, the less specificity of 
“US” techniques, especially when using low diag-
nostic cut-offs, will be probably overcome by the 
advantage of enabling a safer and earlier rule out 
of ACS. More specifically, recent studies showed 
that the use of a low cTn cut-off, equal or close to 
the LoD of the immunoassay, may allow adopting 
Figure 1. Percentage of measurable values of cardiac troponin 
in healthy population.
HS-cTnT - high sensitive cardiac troponin T. HS-cTnI - high sensi-
tive cardiac troponin I. LoD - limit of detection. 99th percentile 
- 99th percentile of a reference healthy population. 
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0h/1h rule-in and rule-out algorithms, maintaining 
virtually the same diagnostic efficiency of the con-
ventional 0h/3h algorithms, but also generating a 
favourable impact, both organizational and eco-
nomic, for patient management in short stay units 
such as the emergency room (13,30,31). Notably, 
0h/2h serial sampling can be seen as a promising 
and reliable alternative to the shorter 0h/1h strat-
egy, especially suited for those facilities where the 
0h/1h algorithm cannot be straightforwardly im-
plemented due to practical reasons (i.e., the emer-
gency room is far from the core laboratory and/or 
efficient means of samples transportation such as 
pneumatic transport system are unavailable) (16).
Conclusions
In conclusion, the gradual introduction in clinical 
practice of the so-called “US” cTn immunoassays 
will need to be anticipated by large and robust 
clinical studies aimed to identify the most suitable 
cut-offs and the most appropriate timing for serial 
sampling to get the most from these new tech-
niques. For the time being, thoughtful translation 
of current diagnostic algorithms to these “US” and 
other incoming cTn immunoassays seems unadvis-
able.
Potential conflict of interest
None declared.
Figure 2. Development of cut-offs for diagnostic algorithms including different cardiac troponin immunoassays. CV10% - coefficient 
of variation value with ≤ 10% analytical imprecision (functional sensitivity). LoD - limit of detection. 99th percentile - 99th percentile 
of a reference healthy population.
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